Spore Biotechnologies

The company has developed a device that uses a combination of photonics, optical technology, and artificial intelligence to detect and quantify bacterial concentrations on-site and in minutes. This system analyzes the light reflected off samples to identify microbial signatures, a stark contrast to conventional methods that require sending samples to external labs, with turnaround times of five to twenty days. The technology is applicable to a wide range of products including food, beverages, pharmaceuticals, and cosmetics, and can detect pathogens like E. coli, Salmonella, and Listeria. By providing immediate results, Spore Biotechnologies enables manufacturers to prevent contaminated product distribution, reduce costly recalls, and enhance consumer safety. Its business model is B2B, serving clients in the FMCG, pharmaceutical, and cosmetics manufacturing sectors.

Spore Biotechnologies has achieved significant milestones, including securing €8 million in a pre-seed funding round in December 2023, followed by a $23 million Series A round in February 2025, bringing its total funding to over $31 million. Key investors include LocalGlobe, Singular, Point 72 Ventures, and Famille C (the Clarins Family Office). The company has also established a crucial academic partnership with the Pasteur Institute to leverage its extensive biobank and enhance the AI model's detection capabilities. After developing and validating its first prototypes, Spore began deploying them in partner factories in May 2024 and plans a full commercial rollout by the end of 2025, with a waitlist for its systems already oversubscribed.